SYNTHETIC CONJUGATE VACCINES AGAINST PLASMODIUM FALCIPARUM

Award Information

Agency: Department of Health and Human Services

Branch: N/A

Contract: N/A

Agency Tracking Number: 13655

Amount: $49,170.00

Phase: Phase I

Program: SBIR

Solicitation Topic Code: N/A

Solicitation Number: N/A

Timeline

Solicitation Year: N/A

Award Year: 1990

Award Start Date (Proposal Award Date): N/A

Award End Date (Contract End Date): N/A

Small Business Information

Univax Biologics, Inc.

12111 Parklawn Dr

Rockville, MD 20852

United States

DUNS: N/A

HUBZone Owned: No

Woman Owned: No

Socially and Economically Disadvantaged: No

Principal Investigator

Name: D Craig Wright
Phone: (301) 770-3099

Business Contact

Phone: () -

Research Institution

N/A

Abstract

THE OVERALL GOAL OF THIS RESEARCH IS THE DEVELOPMENT OF A SYNTHETIC PEPTIDE CONJUGATE VACCINE THAT WILL ELICIT NEUTRALIZING ANTIBODIES AGAINST PLASMODIUM FALCIPARUM SPOROZOITES. THIS PROJECT IS BUILT UPON A PREVIOUSLY IDENTIFIED MURINE MONOCLONAL ANTIBODY RAISED AGAINT P. FALCIPARUM SPOROZOITES THAT PROTECTS MICE AGAINST A P. BERGHEI SPOROZOITE CHALLENGE. THE BINDING SITE OF THIS MONOCLONAL ANTIBODY WAS REVEALED BY EPITOPE MAPPING TO CONSIST OF A DIPEPTIDE SEQUENCE COMMON TO THE CIRCUMSPOROZOITE PROTEINS OF BOTH P. FALCIPARUM AND P. BERGHEI. IN PHASE I, UNIVAX BIOLOGICS, INC., WILL PREPARE SYNTHETIC PEPTIDE CONJUGATE VACCINES AND DETERMINE THEIR PROTECTIVE EFFICACY IN A MURINE MALARIA MODEL. THESE STUDIES WILL LAY THE FOUNDATION FOR THE FURTHER DEVELOPMENT OF CONJUGATE OR RECOMBINANT VACCINES FOR LATER PRECLINICAL STUDIES.

* Information listed above is at the time of submission. *

You are here

SYNTHETIC CONJUGATE VACCINES AGAINST PLASMODIUM FALCIPARUM